Key Takeaways:
Intellia Therapeutics, Inc. (Nasdaq: NTLA) reported a net loss of $96.2 million for the first quarter of 2026 as the company pushed its lead CRISPR-based gene editing candidate for hereditary angioedema (HAE) toward regulatory approval. The results show progress in managing expenses as the firm prepares for potential commercialization.
“With lonvo-z, we achieved a historic milestone by presenting the world’s first Phase 3 data for an in vivo gene editing candidate and initiated a rolling BLA submission as we seek to provide a highly differentiated one-time treatment option to people living with HAE,” John Leonard, President and Chief Executive Officer at Intellia, said.
For the quarter ended March 31, Intellia’s net loss of $96.2 million, or $0.81 per share, was smaller than the $114.3 million loss, or $1.10 per share, recorded in the same period last year. Collaboration revenue was $15.0 million, compared to $16.6 million for the first quarter of 2025. The company’s cash, cash equivalents, and marketable securities stood at $517.2 million, which Intellia stated provides a cash runway at least into 2028.
The firm’s progress with its lead candidate, lonvoguran ziclumeran (lonvo-z), represents a critical step for the entire in vivo gene editing field. A one-time treatment administered in an outpatient setting, lonvo-z is designed to permanently inactivate a gene to eliminate HAE attacks. Intellia is targeting a U.S. launch in the first half of 2027, which could challenge existing HAE treatments if approved.
Beyond HAE, Intellia is advancing nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis, a program co-developed with Regeneron Pharmaceuticals, Inc. The company recently resumed patient screening for its two Phase 3 trials in that program, aiming to complete enrollment for one study in the second half of 2026. This places Intellia in a competitive landscape with other companies targeting rare diseases, such as Sarepta Therapeutics, where regulatory and clinical milestones are closely watched by investors.
Research and development expenses for the quarter were $80.7 million, a decrease from $108.4 million in the first quarter of 2025. General and administrative expenses grew to $34.8 million from $29.0 million in the prior-year period, reflecting investments to support the company's growth and pre-commercial activities.
This article is for informational purposes only and does not constitute investment advice.
